Interesting ImagesUnexpected Detection of Skeletal Muscle Renal Cell Carcinoma Metastasis With 99mTc-EDDA/HYNIC-Tyr3-Octreotide (Tektrotyd) ScanFuoco, Valentina MD∗; Barisella, Marta MD†; Lorenzoni, Alice MD∗; Verzoni, Elena MD‡; Maccauro, Marco MD∗ Author Information From the Departments of ∗Nuclear Medicine †Diagnostic Pathology and Laboratory Medicine ‡Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Received for publication May 2, 2022; revision accepted May 5, 2022. Conflicts of interest and sources of funding: none declared. Correspondence to: Valentina Fuoco, MD, Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Giacomo Venezian No. 1, 20133 Milan, Italy. E-mail: [email protected]. Clinical Nuclear Medicine: December 2022 - Volume 47 - Issue 12 - p e762-e764 doi: 10.1097/RLU.0000000000004302 Buy Metrics Abstract Somatostatin receptor scintigraphy with 99mTc-Tektrotyd is widely used for the investigation of neuroendocrine tumors. Overexpression of somatostatin receptors has been shown in different tumor types including lymphomas, breast carcinoma, and renal cell carcinoma (RCC). Isolated case reports have shown that RCC metastases can be identified using somatostatin receptor imaging such as Octreoscan scintigraphy and 68Ga-DOTATATE PET/CT. We report the case of a 70-year-old man with a history of surgically removed RCC who referred to 99mTc-Tektrotyd scintigraphy for the evaluation of a pancreatic tail lesion. The scan revealed intense tracer uptake in a left splenius cervicis muscle lesion that on biopsy was consistent with metastatic RCC. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.